A Study of the Efficacy and Safety of PPI-668 (NS5A Inhibitor) Plus Sofosbuvir, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype-4

PHASE2/PHASE3UnknownINTERVENTIONAL

Enrollment

300

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

January 31, 2016

Study Completion Date

April 30, 2016

Conditions

Chronic Hepatitis C

Interventions

DRUG

ravidasvir hydrochloride

200 mg

DRUG

sofosbuvir

400 mg

DRUG

ribavirin

1000 mg - 1200 mg per day, weight-based dosing

Trial Locations (3)

Al-Qahira Al-Fatimeya MoH Hospital, Cairo

Kasr El Aini Viral Hepatitis Center, Cairo

National Liver Institute, Menoufiya